Marianna Manfrini

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study.

Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study.

Journal: Lancet (London, England)

Published: October 30, 2025

Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials.

Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials.

Journal: Lancet (London, England)

Published: October 30, 2025

Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK Trial.

Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK Trial.

Journal: Neurology and therapy

Published: September 10, 2025

Quantitative Muscle Magnetic Resonance Outcomes in Patients With Duchenne Muscular Dystrophy: An Exploratory Analysis From the EMBARK Randomized Clinical Trial.

Quantitative Muscle Magnetic Resonance Outcomes in Patients With Duchenne Muscular Dystrophy: An Exploratory Analysis From the EMBARK Randomized Clinical Trial.

Journal: JAMA neurology

Published: May 12, 2025

Estimating drug concentration-response relationships by applying causal inference methods for continuous point exposures and time-to-event outcomes.

Estimating drug concentration-response relationships by applying causal inference methods for continuous point exposures and time-to-event outcomes.

Journal: Statistical methods in medical research

Published: November 15, 2023

ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial.

ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial.

Journal: Journal of neurology

Published: November 10, 2023

Recurrent disability progression endpoints in multiple sclerosis clinical trials.

Recurrent disability progression endpoints in multiple sclerosis clinical trials.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: September 30, 2022

Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis.

Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: June 13, 2022

Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma.

Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma.

Journal: Neuro-oncology advances

Published: October 25, 2021

Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials.

Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials.

Journal: European journal of neurology

Published: December 03, 2020

Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis.

Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis.

Journal: Multiple sclerosis and related disorders

Published: July 30, 2020

Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.

Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.

Journal: JAMA neurology

Published: June 09, 2020

Showing 1-12 of 15

Last Updated: 09/26/2026